Wolff JM
[GnRH Antagonists - A New Therapy Option for Advanced Prostate Cancer.] [JOURNAL ARTICLE]
Aktuelle Urol 2009 Apr 27.
At present medical castration employing luteinis-ing hormone releasing hormone (LHRH) agonists is the standard of care for patients with advanced prostate cancer. LHRH agonists suppress the synthesis of testosterone to a castration level. In contrast to surgical castration, medical castration is reversible. However LHRH agonists induce an initial increase of the testosterone level. This so-called testosterone surge leads to tumour growth and increases the disease-specific complaints, known as flare phenomena. It may be possible that the overall survival of these patients is deteriorated. In contrast, gonado-trophin releasing hormone (GnRH) antagonists do not induce a testosterone surge and the level of testosterone decreases as rapidly as that known from a surgical castration.
More from this journal |
